Photonz - producing high purity EPA from algal fermentation

Photonz's Chief Scientific Officer Wins NZBIO Award

Posted on 20 March 2013

 

The award is presented to an individual under the age of 40 whose work demonstrates the potential for future leadership in New Zealand's bioeconomy.

 

Dr Griffiths won in recognition of his work at Photonz in the development of non-fish eicosapentanoic acid (EPA) produced directly by algal fermentation. 

 

EPA is an increasingly valued ingredient used in the health and pharmaceutical industries. Photonz's EPA is set to be the first viable replacement source for EPA which otherwise can only be extracted from already-at-risk global fish stocks. Dr Griffiths believes in the positive impact on human and animal health that this product can bring, as well as the environmental advantages of production by fermentation rather than extraction from fish resources.

 

“Dr Griffiths has made impressive contributions to the New Zealand bio-science community,” said Dr Greg Collier, CEO, Photonz Corp.  “Working in the commercial setting of an early stage biotechnology enterprise is challenging enough.  But to demonstrate leadership, determination, and remain passionate in his efforts to deliver an ecologically and socially responsible end product, over a seven year span, has amazed us all.”

 

“I'm honoured to receive this award, and I'm extremely grateful to the talented team at Photonz whose hard work and dedication has supported all the progress that we've made,” said Dr Griffiths. 

 

ENDS

 

About Photonz: Founded in New Zealand in 2002, Photonz Corporation produces the omega-3 fatty acid eicosapentaenoic acid (EPA) which is a critical ingredient in novel therapeutics for the cardiovascular disease market. Photonz has proprietary control over a unique fermentation process involving an EPA-rich strain of marine microalgae. This has been shown to produce EPA in a range of purities up to 97% and to be suited to pharmaceutical applications. Photonz is approaching a commercial-ready phase with facilities in the UK and France involved in late-stage up-scaling of an already proven manufacturing process. EPA, which has a range of food-based and therapeutic applications, is otherwise derived from fish oil.

 

News

  • Photonz receives $2.9 million R+D Grant

    Posted on Mar. 28, 2011

    Awarded under the TechNZ programme, the grant will enable the biotech company to undertake work that will, when completed, allow it to commence commercial production of the omega-3 fatty acid eicosapentaenoic acid (EPA) from marine micro-algae....read more
  • Photonz successfully transfers process to industrial scale

    Posted on Nov. 21 2011

    Photonz Corporation has achieved a major milestone on the path to commercially manufacturing, by fermentation, the high-value omega-3 fatty acid, EPA...read more
  • Photonz signs with Novasep

    Posted on Sep. 21 2011

    Biotech company Photonz Corporation has entered into a development agreement with Novasep, a world-class provider of purification technology...read more
Site by Jet Creative Studio